Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study.
drug-induced parkinsonism
parkinsonism
trimetazidine
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
04 10 2020
04 10 2020
Historique:
received:
07
09
2020
revised:
01
10
2020
accepted:
02
10
2020
entrez:
6
10
2020
pubmed:
7
10
2020
medline:
29
12
2020
Statut:
epublish
Résumé
An association between trimetazidine (TMZ), an anti-anginal drug, and parkinsonism has been reported in a number of studies. However, evidence from studies with long-term follow-up and better validity is lacking. We investigated the risk of TMZ-associated parkinsonism, specifically the incidence rate, cumulative dose-response relationship, and combined effects with other parkinsonism-inducing medications. This propensity score-matched retrospective cohort study was conducted using 14-year health insurance claims data in South Korea. The risk of parkinsonism was evaluated using multivariate Cox proportional hazard regression analysis, adjusted for comorbidities and concurrent medications. A total of 9712 TMZ users and 29,116 matched non-TMZ users were included. TMZ users had a significantly higher incidence rate of parkinsonism than non-TMZ users (9.34 vs. 6.71 per 1000 person-years;
Identifiants
pubmed: 33020406
pii: ijerph17197256
doi: 10.3390/ijerph17197256
pmc: PMC7579582
pii:
doi:
Substances chimiques
Trimetazidine
N9A0A0R9S8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Drugs Aging. 2012 Feb 1;29(2):105-18
pubmed: 22250585
Eur J Neurol. 2004 Oct;11(10):709-10
pubmed: 15469457
Neurologia. 2004 Sep;19(7):392-5
pubmed: 15273888
Parkinsonism Relat Disord. 2018 Nov;56:76-81
pubmed: 29934195
Arch Pharm (Weinheim). 2007 Sep;340(9):456-65
pubmed: 17763374
Harv Rev Psychiatry. 2015 Sep-Oct;23(5):354-67
pubmed: 26332218
Biochem Pharmacol. 1995 Nov 9;50(10):1645-50
pubmed: 7503767
Eur J Clin Pharmacol. 2017 Jul;73(7):911-916
pubmed: 28386684
Parkinsonism Relat Disord. 2019 May;62:117-121
pubmed: 30638818
Neuroepidemiology. 2019;52(3-4):220-226
pubmed: 30831572
Ann Pharmacother. 2019 Nov;53(11):1102-1110
pubmed: 31216861
Mov Disord. 2013 Aug;28(9):1222-9
pubmed: 23609436
Cardiology. 2016;135(3):188-195
pubmed: 27415810
Postgrad Med J. 2009 Jun;85(1004):322-6
pubmed: 19528308
Nutr Hosp. 2011 Jul-Aug;26(4):659-68
pubmed: 22470008
Int J Epidemiol. 2017 Apr 1;46(2):e15
pubmed: 26822938
J Clin Neurol. 2012 Mar;8(1):15-21
pubmed: 22523509
Lancet Neurol. 2006 Jan;5(1):75-86
pubmed: 16361025
Am J Med. 2004 Sep 15;117(6):412-9
pubmed: 15380498
Front Neurol. 2020 Feb 25;11:44
pubmed: 32158422
Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1385-1392
pubmed: 30379361
Expert Opin Drug Saf. 2013 Jul;12(4):487-96
pubmed: 23540800
Mov Disord. 2019 Jul;34(7):1014-1021
pubmed: 30938893
Mov Disord. 2017 Feb;32(2):227-234
pubmed: 27779780
J Psychiatr Res. 2014 Nov;58:84-8
pubmed: 25124550
Therapie. 2005 Jul-Aug;60(4):419-22
pubmed: 16268443
Neurosciences (Riyadh). 2013 Jul;18(3):215-21
pubmed: 23887211
Sci Rep. 2019 Feb 8;9(1):1705
pubmed: 30737414
Front Neurosci. 2018 Aug 30;12:612
pubmed: 30214392